Fractyl Health, Inc. (Nasdaq: GUTS), a leading metabolic therapeutics company, has announced its intention to conduct a public offering of its common stock and pre-funded warrants. The offering will include common warrants to purchase additional shares and is subject to market and other conditions. Ladenburg Thalmann & Co. Inc. is serving as the sole book-running manager for the offering. The company plans to use the proceeds to support its Revita and Rejuva pipeline programs, as well as for general corporate purposes. The offering's terms will be detailed in a final prospectus supplement to be filed with the SEC.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。